Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- المؤلفون: Lee, David J.1,2 ; Kumarasamy, Nagalingeswaran3; Resch, Stephen C.4,5; Sivaramakrishnan, Gomathi N.6; Mayer, Kenneth H.1,7,8; Tripathy, Srikanth6; Paltiel, A. David9; Freedberg, Kenneth A.1,2,5,10,11; Reddy, Krishna P.1,2,12
- المصدر:
PLoS ONE. 7/2/2019, Vol. 14 Issue 7, p1-17. 17p.
- الموضوع:
- معلومة اضافية
- الموضوع:
- نبذة مختصرة :
Background: Truenat is a novel molecular assay that rapidly detects tuberculosis (TB) and rifampicin-resistance. Due to the portability of its battery-powered testing platform, it may be valuable in peripheral healthcare settings in India. Methods: Using a microsimulation model, we compared four TB diagnostic strategies for HIV-negative adults with presumptive TB: (1) sputum smear microscopy in designated microscopy centers (DMCs) (SSM); (2) Xpert MTB/RIF in DMCs (Xpert); (3) Truenat in DMCs (Truenat DMC); and (4) Truenat for point-of-care testing in primary healthcare facilities (Truenat POC). We projected life expectancy, costs, incremental cost-effectiveness ratios (ICERs), and 5-year budget impact of deploying Truenat POC in India’s public sector. We defined a strategy “cost-effective” if its ICER was
No Comments.